QVQ HOLDING BV

Their core work

QVQ Holding BV is a Dutch biotech SME based in Utrecht that contributes specialist expertise to EU-funded research training networks in the life sciences. Their work spans two distinct domains: diagnostics of pathogenic fungi (OPATHY) and the pharmacology of G protein-coupled receptors (GPCRs) as therapeutic targets in oncology (ONCORNET2.0). In both cases they operate as a partner within large multi-institutional consortia, indicating they supply a defined technical capability — likely proprietary tools, assays, or biological reagents — rather than general research services. Their participation in MSCA training networks also means they host or co-supervise early-stage researchers, combining R&D output with training functions.

What they specialise in

How they've shifted over time

In their first H2020 project (OPATHY, 2015-2019) QVQ was embedded in infectious disease research, specifically omics-based diagnostics for fungal pathogens — a clinically driven but diagnostics-oriented domain. By their second project (ONCORNET2.0, 2020-2024) the focus had shifted sharply toward receptor pharmacology, cancer biology, and drug discovery, with no apparent thematic overlap with yeast biology. This is a significant pivot, suggesting either a deliberate strategic reorientation toward the oncology and drug target space, or that QVQ possesses cross-cutting molecular tools (such as antibody-based reagents) applicable across both disease contexts.

QVQ appears to be moving toward the high-value drug discovery space, particularly GPCR-targeted therapies in oncology — a commercially active area where SME tool providers with proprietary assay or antibody capabilities are in strong demand from pharma partners.

How they like to work

QVQ has participated exclusively as a consortium partner across both projects and has never served as a project coordinator, indicating a preference — or current capacity — for contributing specialist expertise within larger structures rather than leading them. With 18 unique partners across 9 countries from just two projects, they operate within broad, geographically diverse consortia typical of MSCA training networks. This suggests they are comfortable working as one node among many, and prospective partners should expect a focused, deliverable-bound engagement rather than a co-leadership dynamic.

QVQ has built connections with 18 distinct partners across 9 countries through two MSCA networks, a relatively broad reach for a small company with only two projects. The MSCA-ITN format means these partners are predominantly universities and research institutes, with QVQ likely serving as the industry node bringing applied or commercial perspective to otherwise academic consortia.

What sets them apart

QVQ occupies an uncommon niche as an SME embedded in academic MSCA training networks — most companies of this size are absent from such structures, which require sustained mentorship commitment and scientific credibility. Their combination of infectious disease diagnostics and GPCR drug discovery experience makes them unusual: few SMEs hold validated expertise in both fungal pathology and receptor pharmacology. For a consortium needing an industry partner with real drug discovery context and a track record of hosting doctoral researchers, QVQ fills a slot that is genuinely hard to replace with a larger CRO or pharma company.

Highlights from their portfolio

• ONCORNET2.0
  The largest-funded project (€265,620) and the one with the richest keyword profile, placing QVQ directly in the commercially significant GPCR drug discovery space alongside an international oncology research network.
• OPATHY
  Demonstrates QVQ's earlier presence in omics-based diagnostics for fungal pathogens — a thematically distinct domain that reveals breadth of biological expertise beyond their current oncology focus.